4P-Pharma will give a talk during the DDIP 2020

4P-Pharma’s CSO, Patrice Denèfle, will give a talk on 4P004 : « Accelerating therapeutic innovation for patient through drug repurposing : a use case in Osteoarthritis » at the Drug Discovery Innovation Programme (DDIP) virtual meeting organized by the World BI, on November, 17th 2020, 10:00 a.m CET.

To learn more about 4P-Pharma, our pipeline and our partnerships, please feel free to contact Patrice or Roselina Lam, our Business Developer, via email.

For further information, please follow the link :

4P-Pharma appoints Patrice Denèfle as Chief Scientific Officer

4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO).

 “We are delighted to welcome Patrice to our team as Chief Scientific Officer. […] I look forward to work closely with him to push forward 4P-Pharma’s strong momentum”, said Revital Rattenbach, Founder and President of 4P-Pharma.

“I am thrilled to join 4P-Pharma team as CSO, as the company has a very impressive record of innovative projects. […] I am looking forward to work with all the team of 4P-Pharma and its scientific and advisory board to support and boost the clinical development of 4P004 and bring my expertise to expand 4P-Pharma’s portfolio drug candidates”, said Patrice Denèfle.

Patrice Denèfle, Chief Scientific Officer

Read the full press release
English version: 202005_PR_4P-Pharma_Denefle_vEN
French version: 202005_PR_4P-Pharma_Denefle_vFR

4P-Pharma press contact
Roselina Lam, Business development and Licensing Manager
Phone: +33 (0)9 50 72 97 68 – E-mail: